Compare GRWG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRWG | ACET |
|---|---|---|
| Founded | 2008 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.2M | 77.3M |
| IPO Year | 2015 | 2017 |
| Metric | GRWG | ACET |
|---|---|---|
| Price | $1.28 | $8.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 645.9K | 137.9K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,365,479.00 | N/A |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.51 | N/A |
| 52 Week Low | $0.93 | $0.46 |
| 52 Week High | $2.40 | $9.05 |
| Indicator | GRWG | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 61.66 |
| Support Level | $1.02 | $6.28 |
| Resistance Level | $1.61 | $8.46 |
| Average True Range (ATR) | 0.09 | 0.51 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 42.31 | 82.18 |
GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).